title: No interruption of lactation is needed after (11)C-WAY 100635 or (11)C-raclopride PET.
authors.forename: Eydie L
authors.initials: EL
authors.lastname: Moses-Kolko
authors.forename: Carolyn Cidis
authors.initials: CC
authors.lastname: Meltzer
authors.forename: Joseph C
authors.initials: JC
authors.lastname: Helsel
authors.forename: Michael
authors.initials: M
authors.lastname: Sheetz
authors.forename: Chestera
authors.initials: C
authors.lastname: Mathis
authors.forename: James
authors.initials: J
authors.lastname: Ruszkiewicz
authors.forename: Debra
authors.initials: D
authors.lastname: Bogen
authors.forename: Andrea L
authors.initials: AL
authors.lastname: Confer
authors.forename: Katherine L
authors.initials: KL
authors.lastname: Wisner
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D007774:Lactation / Q000378:metabolism*; D008895:Milk, Human / Q000737:chemistry*; D010879:Piperazines / Q000032:analysis / Q000493:pharmacokinetics*; D049268:Positron-Emission Tomography / Q000379:methods; D011725:Pyridines / Q000032:analysis / Q000493:pharmacokinetics*; D020891:Raclopride / Q000032:analysis / Q000493:pharmacokinetics*; D011829:Radiation Dosage; D011874:Radiometry / Q000379:methods*; D019275:Radiopharmaceuticals / Q000032:analysis / Q000493:pharmacokinetics; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors
chemical_list: D010879:Piperazines; D011725:Pyridines; D019275:Radiopharmaceuticals; D020891:Raclopride; C090413:N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide